BK4494 Biotechnology
- 1061.485
- -5.477-0.51%
Earnings Call Summary | COVALON TECHNOLOGIES LTD(CVALF.US) Q2 2024 Earnings Conference
The following is a summary of the Covalon Technologies Ltd. (CVALF) Q2 2024 Earnings Call Transcript:Financial Performance:Covalon reported a Q2 revenue increase of 16.1% to $8.4 million, up from $7.2
Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
The following is a summary of the IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript:Financial Performance:IntelGenx reported Q4 total revenue of $426,000, a 146% increase compared t
Covalon Technologies Ltd. GAAP EPS of -C$0.03
Satellos Bioscience Inc. GAAP EPS of -C$0.03
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
ProMIS Neurosciences Inc Files For Shelf Of Up To 22.1M Common Shares By Selling Stockholders
MedMira Inc. GAAP EPS of C$0.00
NurExone Biologic Inc. Reports Q1 Results
Rakovina Therapeutics Inc. GAAP EPS of -$0.01
Weekly FDA Drug Pipeline Calendar (April 24 - April 28)
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
XORTX Therapeutics Inc. Gets FDA Orphan Drug Designation For Oxypurinol For Treatment Of Autosomal Dominant Polycystic Kidney Disease
Ceapro Inc. GAAP EPS of C$0.06, Revenue of C$18.84M
NurExone Biologic Inc. GAAP EPS of -$0.10
Reported Late Thursday Feb 9, BriaCell Therapeutics Corp. Announces Results Of Shareholder Meeting; Approval Of The Company's New Omnibus Equity Incentive Plan
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to
Xortx Therapeutics Inc Filed For Mixed Shelf Of Up To $50M
Xortx Therapeutics Inc Filed For Mixed Shelf Of Up To $50M
On Jan 23, 2023, Midatech Pharma PLC Received Termination Notice From Bioasis Technologies Inc. To Terminate Arrangement; On January 26 Co Terminated Securities Purchase Agreement By And Between Company And A Certain Institutional Investor
On Jan 23, 2023, Midatech Pharma PLC Received Termination Notice From Bioasis Technologies Inc. To Terminate Arrangement; On January 26 Co Terminated Securities Purchase Agreement By And Between Compa
Comparing Baudax Bio (NASDAQ:BXRX) & Curative Biotechnology (OTCMKTS:CUBT)
Curative Biotechnology (OTCMKTS:CUBT – Get Rating) and Baudax Bio (NASDAQ:BXRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two business
Shenzhen Bioeasy Biotechnology Unit Gets Registration Certificates for Medical Devices
01:45 AM EDT, 10/24/2022 (MT Newswires) -- Shenzhen Xiupu Biotechnology, a unit of Shenzhen Bioeasy Biotechnology (SHE:300942), received registration certificates from the Guangdong Provincial Drug Ad
Assenagon Asset Management S.A. Acquires 162,531 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)
Assenagon Asset Management S.A. boosted its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) by 651.2% in the 2nd quarter, according to its most recent Form 13F filing with
Commonwealth Equity Services LLC Sells 173 Shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE)
Commonwealth Equity Services LLC trimmed its position in shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating) by 1.8% during the 2nd quarter, according to its most re
CX Institutional Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)
CX Institutional purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) during the second quarter, Holdings Channel.com reports. The firm purchased 29,812 shares of